Visikol is a contract research organization that specializes in advanced drug discovery solutions including 3D cell culture assays and tissue imaging utilizing high content screening and confocal microscopy, as well as digital pathology and AI solutions for histological analysis of tissue sections. Since its inception in 2012, Visikol has developed a portfolio of tissue imaging and analysis technologies that allow for the transformation of tissues and cells into quantitative data sets that can be mined for actionable insights.

As a company, Visikol is focused on shifting the paradigm of how tissues and cells are analyzed from a qualitative human-driven approach to a quantitative computer vision driven approach. Visikol offers services to pharmaceutical and biotech clients to help them accelerate their drug discovery efforts and to reduce the translational gap between in vitro and in vivo studies through the use of advanced cell culture models and analysis techniques.